Eneda Toska - Concepedia

Author

Eneda Toska

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

E Toska, E. Toska, Eneda Toska, Toska E

177

Publications

5.1K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center University at Buffalo, State University of New York Cornell University AstraZeneca (United States)Johns Hopkins University

About

Eneda Toska is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, cell biology, and cell signaling.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	1.3K
2	Cell Biology	11	11	1.2K
3	Social Sciences	2	2	65
4	Natural Sciences	1	1	70
5	Public Health	1	1	22

Eneda Toska

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer Ana Bosch, Zhiqiang Li, Anna Bergamaschi, Science Translational Medicine	2015	418
Double <i>PIK3CA</i> mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors Neil Vasan, Pedram Razavi, Jared L. Johnson, Science	2019	281
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D Eneda Toska, Hatice U. Osmanbeyoglu, Pau Castel, Science	2017	260
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer Guotai Xu, Sagar Chhangawala, Emiliano Cocco, Nature Genetics Radiation OncologyBreast OncologyMedicineTherapeutic ResponseEstrogen-receptor-positive Breast Cancer	2020	225
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition Pau Castel, Haley Ellis, Ružica Bago, Cancer Cell Molecular PhysiologySignal TransductionPi3kα InhibitionSignaling PathwayCell Regulation	2016	222
Resistance to TRK inhibition mediated by convergent MAPK pathway activation Emiliano Cocco, Alison M. Schram, Amanda Kulick, Nature Medicine Signal TransductionCell RegulationMolecular PathwaySignaling PathwayReceptor Tyrosine Kinase	2019	214
The present and future of PI3K inhibitors for cancer therapy Pau Castel, Eneda Toska, Jeffrey A. Engelman, Nature Cancer Pi3k InhibitorsMedicinePharmacologyCancer GrowthAnti-cancer Agent	2021	207
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma Patrizia Mondello, Saber Tadros, Matt Teater, Cancer Discovery	2020	155
FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer Amaia Arruabarrena-Aristorena, Jesper L.V. Mååg, Srushti Kittane, Cancer Cell ChromatinInfluence Therapeutic ResponseSomatic VariantChromatin StructureBreast Oncology	2020	130
Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer Anna Bianchi, Iago De Castro Silva, Nilesh Deshpande, Cancer Discovery	2023	116

Page 1